Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil)
- eletriptan
Interactions between your drugs
nelfinavir eletriptan
Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil), eletriptan
Nelfinavir may significantly increase the blood levels and effects of eletriptan, which in some cases can lead to excessive narrowing of blood vessels in the body. This can reduce blood flow to vital organs and increase the risk of rare but serious side effects such as high blood pressure, heart attack, stroke, and gangrene (death of tissues, usually in the arm or leg, that may require surgical amputation). In general, you should not use eletriptan until at least 72 hours after the last dose of eletriptan. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience numbness, tingling, chest pain or tightness, shortness of breath, or irregular heartbeat, as these may be signs and symptoms of excessive eletriptan levels. Do not take larger doses or use the drug more frequently than prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
tenofovir food
Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil)
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Dovato
Dovato is a complete HIV-1 treatment regimen in one tablet that may be used in adults and children ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.